

## **Pharmacy Drug Policy Checklist**

POLICY NAME | Wegovy (semaglutide) | POLICY # 3248P

## Criteria

Coverage Criteria	
	Treatment is being requested to reduce the risk of major adverse cardiovascular (heart) events (cardiovascular (heart related) death, non-fatal heart attack, or non-fatal stroke)
	Age 45 years or older
	Documentation patient has obesity as confirmed by a body mass index ≥27
	Documentation patient has established cardiovascular (heart) disease as evidenced by one of the following:  • Prior heart attack
	Prior stroke (ischemic or hemorrhagic stroke)
	<ul> <li>Peripheral arterial disease (such as intermittent claudication with ankle-brachial index &lt;0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic heart disease)</li> </ul>
	Wegovy will be used as an adjunct to lifestyle modification (dietary restriction, exercise, etc)  • For State of Illinois members: participation in Virta Health or equivalent Health Alliance supported lifestyle management program if member is excluded from Virta Health is required
	Prescribed by or in consultation with a cardiologist (heart doctor)
	Patient is receiving standard of care treatment for heart disease as appropriate/indicated including an antiplatelet agent (such as clopidogrel), lipid-lowering drug (such as atorvastatin), antihypertensive (such as lisinopril)
Exclusion Criteria – Any of the following prevents coverage	
	Request for coverage is solely for weight loss
	History of type 1 or type 2 diabetes
	New York Heart Association Class IV (4) heart failure
	Wegovy will not be covered in combination with any other GLP-1 agonists (such as Ozempic)